K. N. Chi Et Al. , "TITAN: A randomized, double-blind, placebo-controlled, phase 3 trial of apalutamide (ARN-509) plus androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC)," 41st Annual Congress of the European-Society-for-Medical-Oncology (ESMO) , vol.27, Copenhagen, Denmark, 2016
Chi, K. N. Et Al. 2016. TITAN: A randomized, double-blind, placebo-controlled, phase 3 trial of apalutamide (ARN-509) plus androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC). 41st Annual Congress of the European-Society-for-Medical-Oncology (ESMO) , (Copenhagen, Denmark).
Chi, K. N., Chowdhury, S., Radziszewski, P., Lebret, T., Ozguroglu, M., Sternberg, C., ... Sims, R. B.(2016). TITAN: A randomized, double-blind, placebo-controlled, phase 3 trial of apalutamide (ARN-509) plus androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC) . 41st Annual Congress of the European-Society-for-Medical-Oncology (ESMO), Copenhagen, Denmark
Chi, K. Et Al. "TITAN: A randomized, double-blind, placebo-controlled, phase 3 trial of apalutamide (ARN-509) plus androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC)," 41st Annual Congress of the European-Society-for-Medical-Oncology (ESMO), Copenhagen, Denmark, 2016
Chi, K. N. Et Al. "TITAN: A randomized, double-blind, placebo-controlled, phase 3 trial of apalutamide (ARN-509) plus androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC)." 41st Annual Congress of the European-Society-for-Medical-Oncology (ESMO) , Copenhagen, Denmark, 2016
Chi, K. N. Et Al. (2016) . "TITAN: A randomized, double-blind, placebo-controlled, phase 3 trial of apalutamide (ARN-509) plus androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC)." 41st Annual Congress of the European-Society-for-Medical-Oncology (ESMO) , Copenhagen, Denmark.
@conferencepaper{conferencepaper, author={K. N. Chi Et Al. }, title={TITAN: A randomized, double-blind, placebo-controlled, phase 3 trial of apalutamide (ARN-509) plus androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC)}, congress name={41st Annual Congress of the European-Society-for-Medical-Oncology (ESMO)}, city={Copenhagen}, country={Denmark}, year={2016}}